Article (Published version) (534 Kb) - Limited access to UNIGE
Use of pneumococcal polysaccharide vaccine in children: what is the evidence?
|Published in||Current Opinion in Infectious Diseases. 2012, vol. 25, no. 3, p. 292-303|
|Abstract||Pneumococcal glycoconjugate vaccines (PCVs) are now widely used in infant immunization schedules. These vaccines are also recommended for those at increased risk of pneumococcal infection and to provide optimal serotype coverage to those at increased risk of disease. The 23-valent polysaccharide vaccine (PPV23) is often advised from the second birthday to provide broader serotype coverage. The use of pneumococcal polysaccharide vaccines (PPVs) has in recent years become a topic of much debate, especially for use in children.|
|Keywords||Adolescent — Child — Child, Preschool — Glycoconjugates/immunology — Humans — Immunization, Secondary/adverse effects — Immunocompromised Host — Infant — Pneumococcal Infections/prevention & control — Pneumococcal Vaccines/administration & dosage/adverse effects/immunology — Recurrence — Risk Factors — Vaccines, Conjugate/immunology|
|Research group||Centre de Vaccinologie et d'Immunologie néonatale (177)|
|BORROW, Ray, HEATH, Paul T, SIEGRIST, Claire-Anne. Use of pneumococcal polysaccharide vaccine in children: what is the evidence?. In: Current Opinion in Infectious Diseases, 2012, vol. 25, n° 3, p. 292-303. doi: 10.1097/QCO.0b013e3283531b0f https://archive-ouverte.unige.ch/unige:31385|